The IPO market has returned to life after a pandemic-induced lull and today’s offers are all in the biotech and health care space.
The freshly restored U.S. market for going publics is anticipating 5 offers to price this week, including one that could end up being the most significant deal of the year to date.
” Royalty Pharma is highly rewarding and creates strong cash flow, and it plans to pay a dividend with 2.3%yield at the midpoint,” said Renaissance Capital, a company of institutional research and IPO ETFs, in commentary.
The business has used to list on Nasdaq under the ticker sign “RPRX.” There are 13 banks underwriting the offer, led by J.P. Morgan.
” Because our starting in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research study hospitals and not-for-profits through small and mid-cap biotechnology business to leading global pharmaceutical business,” the business says in its IPO documents.
Royalty Pharma has actually constructed a portfolio of royalties by co-funding late-stage clinical trials in return for future royalties, and by getting existing royalties from the initial designers of drugs. The portfolio consists of such drugs as Tysabri, an immunosuppressive drug that is utilized to deal with multiple sclerosis and Crohn’s disease, and Imbruvica, a small particle drug used to treat B cell cancers such as mantle cell lymphoma.
” In 2019, a total of 22 treatments in our portfolio each generated 2019 end-market sales of more than $1 billion, consisting of seven treatments that each produced 2019 end-market sales of more than $3 billion,” the business says.
Proceeds of the IPO will be used for basic corporate functions and to make acquisitions if appropriate.
The other offers this week are all in the biotech and health care sector.
Oncology biotech Forma Therapy Holdings Inc.
is planning to offer 11.8 million shares priced at $16 to $18 each to raise up to $212 million. The stock is anticipated to note on the Nasdaq under the ticker symbol “FMTX.”
Jefferies, SVB Leerink and Credit Suisse are the joint book-running managers. The business taped a bottom line of $348 million on partnership profits of $1006 million in 2019, after earnings of $5.3 million on collaboration income of $1641 million in 2018.
Biotech Progenity Inc.
is preparing to offer 6.7 million shares priced at $14 to $16 each, raising up to $1072 million. The business has actually used to list on Nasdaq under the ticker sign “PROG.”
Piper Sandler, Wells Fargo, Baird, Raymond James and BTIG are underwriters on the offer. Proceeds will be utilized for R&D and for working capital and general business functions.
Don’t miss: Why virus stocks are driving market volatility
” We are a biotechnology business with a recognized record of success in developing and commercializing molecular screening products in addition to innovating in the field of accuracy medicine,” states the prospectus.
Another oncology biotech Repare Therapies Inc.
strategies to offer 7.4 million shares priced at $16 to $18 each to raise $1332 million. The business has used to note on Nasdaq under the ticker sign ‘RPTX.”
Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler are underwriting the offer. Proceeds will be used to finance clinical trials, to money other R&D and for working capital and basic corporate functions.
The business had a loss of $126 million in the first quarter, larger than the loss of $4.8 million published in the year-earlier period.
Rounding out the list is Chinese cancer diagnostics supplier Genetron Holdings Ltd
The stock is expected to be noted on the Nasdaq under the ticker symbol “GTH.” Credit Suisse and CICC are the joint book-running supervisors.
The business recorded a net loss of RMB6760 million ($955 million) on revenue of RMB3234 million in 2019, after a loss of RMB4650 million on profits of RMB2252 million in 2018.
The ETF has taken advantage of the inclusion in the fund of current deals involving companies that just recently went public and that are flourishing in the pandemic, consisting of Zoom Video Communications Inc.
and Slack Inc.